Takeda announced that the recently FDA-approved HyHub and HyHub Duo devices are now available in the U.S. for patients 17 years of age and older, as prescribed, who are prescribed HYQVIA [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase]. The dedicated devices allow HYQVIA, a facilitated subcutaneous immunoglobulin (SCIg) infusion comprised of dual vial units (DVUs) of immunoglobulin and hyaluronidase, to be transferred from vials without using a needle or pooling bag in a home environment or clinical setting. HyHub and HyHub Duo simplify HYQVIA administration by reducing the number of steps to prepare the infusion of two DVUs or more.
Health Technology Insights: ExaCare AI Raises $30 Million to Transform Nursing Admissions
“We collaborated with patients self-infusing HYQVIA and infusion nurses, highlighting their collective need for a simplified preparation process, standardized ancillary supplies, and greater mobility during infusion,” said Uthra Sundaram, senior vice president and head of Takeda’s U.S. Plasma-Derived Therapies Business Unit. “By listening closely to our patients and healthcare partners, we customized these devices to help streamline the infusion preparation experience. The launch of HyHub and HyHub Duo marks the culmination of years of dedicated innovation rooted in real-world needs.”
Health Technology Insights: Microsoft Expands Dragon Copilot AI for Nurses and Partners
HyHub and HyHub Duo reduce the number of steps required to prepare the IG and hyaluronidase of the HYQVIA infusion by up to half compared to infusing with a pooling bag, depending on the device and number of DVUs used. HyHub and HyHub Duo also reduce the ancillary supplies required to prepare the infusion and a dedicated carrier bag is available for convenience that enables limited mobility, such as moving from room to room.
HyHub and HyHub Duo are now available in the U.S. for use only with HYQVIA in patients 17 years of age and older, as prescribed. Patients receiving HYQVIA who are interested in getting started with HyHub or HyHub Duo should talk to their doctor and contact their specialty pharmacy for more information. Patients will receive HyHub or HyHub Duo at no additional cost, and may only begin using the device after receiving appropriate training from a healthcare provider. In the United States, HYQVIA is indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients two years of age and older, and for chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy in adults. It was first approved in the United States in 2014.
Health Technology Insights: INITIO Medical Named First ICPO Theranostics Center in North America
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
